Loading…
Arbutus Biopharma Corporation is projected to rise to $5.58 by 2027, a +16% move from its current price of $4.80. ABUS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.69 | $4.80 | $4.91 | -0.03% |
| Jul 14 | $4.64 | $4.80 | $4.96 | -0.07% |
| Jul 15 | $4.61 | $4.80 | $4.99 | -0.10% |
| Jul 16 | $4.58 | $4.79 | $5.02 | -0.14% |
| Jul 17 | $4.55 | $4.79 | $5.05 | -0.17% |
| Jul 18 | $4.53 | $4.79 | $5.07 | -0.20% |
| Jul 19 | $4.50 | $4.79 | $5.09 | -0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.50 | $4.79 | $5.09 | -0.24% |
| Week 2 | $4.38 | $4.78 | $5.21 | -0.48% |
| Week 3 | $4.28 | $4.77 | $5.30 | -0.71% |
| Week 4 | $4.20 | $4.75 | $5.38 | -0.95% |
| Week 5 | $4.13 | $4.74 | $5.44 | -1.19% |
| Week 6 | $4.07 | $4.73 | $5.50 | -1.42% |
| Week 7 | $4.01 | $4.72 | $5.55 | -1.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc.
to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 and is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation (ABUS) is a healthcare stock currently priced at $4.80 with a market cap of $948.18M and a rank of 2588. The stock sits in a position where the price outlook shows expansion over the forecast horizon, from a 2026 average price of $4.80 to a 2050 average price of $42.88, with upside scenarios up to $74.85 in 2050. The forecast imply a long-run uptrend with multiple years showing bullish sentiment.
A major floor 24.7% below — a decisive break under it would weaken the trend.
The nearest floor, 14.2% below — buyers have tended to step in here.
The nearest ceiling, 8.7% above — a clean break opens room to run.
A major ceiling 21.1% above — clearing it would confirm fresh momentum.
Key ABUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.06 | Sell | $4.98 | Sell |
| MA 10 | $4.90 | Sell | $4.89 | Sell |
| MA 20 | $4.65 | Buy | $4.74 | Buy |
| MA 50 | $4.47 | Buy | $4.56 | Buy |
| MA 100 | $4.45 | Buy | $4.47 | Buy |
| MA 200 | $4.44 | Buy | $4.32 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.68 | Neutral |
| Stoch RSI (14) | 13.76 | Buy |
| CCI (20) | 39.06 | Neutral |
| Williams %R (14) | -51.85 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 7.87 | Buy |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 48.15 | Neutral |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.52 | Buy |
| Ultimate (7,14,28) | 52.98 | Neutral |
| Momentum (10) | 0.39 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 5.17 | Sell |
| ADX (14) | 21.99 | Buy |
| ATR (14) | 0.11 | Info |
On the near term, the technical picture is bullish. The RSI (14-day) is 50. The 50-day simple moving average is $4.47 and the 200-day simple moving average is $4.44. Key support is at $4.12 and resistance at $5.22, with the 30-day range running from $4.12 to $5.59.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.67 | $4.80 | $5.82 | 0% | Neutral | |
| $4.50 | $5.58 | $7.27 | +16% | Neutral | |
| $4.83 | $6.13 | $8.25 | +28% | Bullish | |
| $5.72 | $7.39 | $10.21 | +54% | Bullish | |
| $6.93 | $9.11 | $12.85 | +90% | Bullish | |
| $7.38 | $9.86 | $14.17 | +105% | Bullish | |
| $7.77 | $10.52 | $15.38 | +119% | Bullish | |
| $8.02 | $11.01 | $16.33 | +129% | Bullish | |
| $8.67 | $12.06 | $18.14 | +151% | Bullish | |
| $10.56 | $14.86 | $22.65 | +210% | Bullish | |
| $14.29 | $21.24 | $34.21 | +343% | Bullish | |
| $26.32 | $42.88 | $74.85 | +793% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.67 | $4.80 | $5.73 | +0.00% |
| August 2026 | $3.99 | $4.70 | $5.66 | -2.18% |
| September 2026 | $3.93 | $4.65 | $5.66 | -0.91% |
| October 2026 | $4.00 | $4.75 | $5.83 | +2.17% |
| November 2026 | $3.98 | $4.75 | $5.86 | -0.11% |
| December 2026 | $3.91 | $4.69 | $5.82 | -1.30% |
Click any year to see its month-by-month ABUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ABUS is projected to trade between $3.67 and $5.82, averaging $4.80 — a potential gain of 0% from today's $4.80. Price action looks broadly range-bound.
Arbutus Biopharma Corporation's 2027 outlook centres on $5.58, within a $4.50 to $7.27 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ABUS could reach as high as $8.25, with a base case around $6.13 and support toward $4.83 — roughly +28% from $4.80. Momentum favours further upside here.
Expect ABUS to range from $5.72 to $10.21 through 2029. The $7.39 average target implies a +54% move from current prices. That is up +21% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ABUS price prediction for 2030 points to an average of $9.11 (low $6.93, high $12.85) — a potential gain of +90% on today's $4.80. Momentum favours further upside here.
In 2031, ABUS is projected to trade between $7.38 and $14.17, averaging $9.86 — a potential gain of +105% from today's $4.80. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Arbutus Biopharma Corporation's 2032 outlook centres on $10.52, within a $7.77 to $15.38 range. That is up +7% on the projected 2031 average. That marks a +119% change versus current levels. Momentum favours further upside here.
By 2033, ABUS could reach as high as $16.33, with a base case around $11.01 and support toward $8.02 — roughly +129% from $4.80. Buyers look set to stay in control over this stretch.
Expect ABUS to range from $8.67 to $18.14 through 2034. The $12.06 average target implies a +151% move from current prices. That is up +10% on the projected 2033 average. Momentum favours further upside here.
The ABUS price prediction for 2035 points to an average of $14.86 (low $10.56, high $22.65) — a potential gain of +210% on today's $4.80. Buyers look set to stay in control over this stretch.
In 2040, ABUS is projected to trade between $14.29 and $34.21, averaging $21.24 — a potential gain of +343% from today's $4.80. That is up +43% on the projected 2035 average. Momentum favours further upside here.
Arbutus Biopharma Corporation's 2050 outlook centres on $42.88, within a $26.32 to $74.85 range. That is up +102% on the projected 2040 average. That marks a +793% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABUS today (≈ 208.333333 ABUS) could be worth
$8,933.41
+$7,933.41 (+793%) by 2050 · US Dollar
Based on the average projected ABUS price of $42.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABUSwould be worth at today's price.
$1,000 invested in ABUS on Jul 10, 2025 (≈ 304.878051 ABUS) would be worth
$1,463.41
+$463.41 (+46.3%) today · 1.46× · US Dollar
Based on a ABUS entry price of $3.28 vs. today's $4.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.87 | $985.63 | -1.4% |
| 1 month ago | $4.12 | $1,165.05 | +16.5% |
| 3 months ago | $4.15 | $1,156.63 | +15.7% |
| 6 months ago | $4.5 | $1,066.67 | +6.7% |
| 1 year ago | $3.28 | $1,463.41 | +46.3% |
| All time (5.0y) ago | $2.84 | $1,690.14 | +69.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABUS forecast.
Our base-case forecast reaches $9.60 around 2031.
Implied market cap at $9.60: $1.9B
The multi-year forecast shows a rising trajectory with the 2026 average price at $4.80, the 2027 average at $5.58, the 2028 average at $6.13, the 2029 average at $7.39, and the 2030 average at $9.11. By 2040 the average price is projected at $21.24, and by 2050 it reaches $42.88, with a max scenario of $74.85. Cumulative upside is substantial, with ROI projected to reach 89.8% in 2030 and 793.3% by 2050, and sentiment turning bullish in later years including 2030, 2040, and 2050.
These figures indicate meaningful longer-term upside while acknowledging the uncertainty inherent in price forecasts.
Tap a question to reveal the answer.
In 2030, the average price is expected to be $9.11, with a range of $6.93 to $12.85 and an ROI of 89.8%, with bullish sentiment.
The outlook shows significant upside over time, with the 2026 average price at $4.80 and the 2050 average at $42.88, a max of $74.85, and an ROI up to 793.3%, with bullish sentiment in the longer term; these are estimates, not guarantees.
Yes. The forecast shows a 2029 max of $10.21 and a 2030 max of $12.85, indicating that $10 could be reached in the near to mid-term.
The current price is $4.80 and the market cap is $948.18M.
For 2050, the forecast shows an average price of $42.88, a minimum of $26.32, a maximum of $74.85, and an ROI of 793.3%, with bullish sentiment.
Arbutus Biopharma Corporation Community Discussion
0Share your Arbutus Biopharma Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.